Chordate Medical to establish representative office in Saudi Arabia

Chordate Medical Holding (publ) is opening a representative office in Riyadh, via Chordate Medical AB, to continue to grow in Saudi Arabia and expand its operations to the other countries in the GCC (Gulf Cooperation Council). The general manager of the office will be Alain Durante, who has almost 20 years of sales and marketing experience in medical technology in Saudi Arabia.

"The ongoing implementation of insurance compensation in Saudi Arabia has the potential to lead more quickly to corresponding compensation codes in other countries within the GCC as there is an established cooperation between them. We want to build on our market position for rhinitis in Saudi Arabia as early as possible and expand it to other countries in the immediate area. Saudi Arabia accounts for 55 percent of the medtech market in the Gulf region according to external analyzes, so it is natural that we now establish a local presence there", says Anders Weilandt, CEO of Chordate Medical.

Saudi Arabia is one of the markets that Chordate Medical has selected to prove the market potential of K.O.S treatment in order to enable growth and attract buyers of the company. In November 2020, private health insurance companies in Saudi Arabia approved the insurance code that can be used by private care providers in the country when treating with K.O.S for chronic rhinitis, and at the end of 2021, the first insured K.O.S treatment was carried out in the country.

"With the establishment of a representative office in Riyadh, we are taking the next step to grow further. We see that we have the same potential in other markets in the GCC, such as Qatar, Kuwait, Bahrain and the United Arab Emirates".

The registration process for the establishment of the representative office is underway and can take up to six months. Such an office has a special status in Saudi Arabia because it does not handle trade or transactions, and in Chordate's case it will consist of Alain Durante in the role of General Manager.

"Alain has been responsible for the successful work so far as an employee of our distributor Al Mothihel Trading in Jeddah. In his new role, Alain will continue working with Al Mothihel but also gradually find new opportunities for Chordate in the region", says Anders Weilandt.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277

The following documents can be retrieved from beQuoted

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel, and Saudi Arabia. Chordate Medical's share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at

Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vastra Hamnen Corporate Finance AB, +46 40 200 250,

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact